This study is for patients with lymph node positive or metastatic kidney cancer that is inoperable. The purpose of the study is to see if we increase the time without a patient's kidney cancer getting worse or requiring surgery by adding radiation therapy to the usual immune therapy
This study is for women with inflammatory breast cancer. This study is being done to see if by adding the drug olaparib to the usual radiation therapy will lower the chance of their cancer returning.
This study is for men with prostate cancer that has come back after surgery. This study is being done to see if PET/CT scans help provide more tailored treatment recommendations and outcomes for men who have prostate cancer after radical prostatectomy (RP) and will adding focal, metastasis directed radiation treatment (e.g.., stereotactic radiation) and/or additional systemic therapy (e.g., apalutamide) to standard of care treatment help to delay progression of prostate cancer in men who have already had an RP and now have recurrence?
This study is for men with unfavorable intermediate risk prostate cancer, a low gene risk score and plan to receive radiation therapy with hormone therapy. The purpose of the study is to answer to find out if radiation therapy alone is as effective at controlling the cancer compared to the usual combination of radiation and hormone therapy. The study is also going to determine if adding another new hormone therapy drug to the usual combination of radiation and hormone therapy increase the length of time without the prostate cancer spreading compared to the usual treatment.
This study is for men and women with breast cancer. The purpose of this study is to compare the usual treatment of breast radiation and hormonal drugs after lumpectomy to using hormonal drugs alone.